TARO
NYSETaro Pharmaceutical Industries Ltd.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Website
News25/Ratings4
Latest news
25 items- SECSEC Form 15F-12B filed by Taro Pharmaceutical Industries Ltd.15F-12B - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Filer)
- SECSEC Form 25-NSE filed by Taro Pharmaceutical Industries Ltd.25-NSE - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
- PRSun Pharma Completes Taro MergerCombined entity is better positioned to compete in increasingly competitive generics industry MUMBAI, India and PRINCETON, N.J., June 24, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro") with its subsidiary. As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates. As a result of the merger, Taro is now a private company and wholly-own
- 13D/GAmendment: SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd.SC 13D/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
- SECAmendment: SEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd.SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
- SECSEC Form 6-K filed by Taro Pharmaceutical Industries Ltd.6-K - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Filer)
- SECSEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
- NEWSSun Pharmaceutical And Taro Pharmaceutical Industries' Merger Agreement Was Approved By The Affirmative Vote Of Taro Shareholders
- PRTaro Shareholders Approve Merger with Sun PharmaMUMBAI, India and NEW YORK, May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro shareholders unaffiliated with Sun Pharma) at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024. The details of the merger agreement were announced on January 17, 2024.
- SECSEC Form 6-K filed by Taro Pharmaceutical Industries Ltd.6-K - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Filer)
- SECSEC Form 6-K filed by Taro Pharmaceutical Industries Ltd.6-K - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Filer)
- NEWSTaro Pharmaceutical Indus Q4 Adj EPS $0.43 Beats $0.31 Estimate, Sales $164.941M Beat $156.062M EstimateTaro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.31 by 38.71 percent. The company reported quarterly sales of $164.941 million which beat the analyst consensus estimate of $156.062 million by 5.69 percent. This is a 12.52 percent increase over sales of $146.587 million the same period last year.
- PRTaro Provides Results for Year Ended March 31, 2024Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compared to March 31, 2023 Net sales of $164.9 million increased $18.4 million, or 12.5%, principally due to new launches and gross-to-net ("GTN") adjustments. Excluding the impact of GTN adjustments, sales growth was high single digits. Gross profit of $87.4 million (53.0% of net sales) compared to $75.7 million (51.6% of net sales). Research and development (R&D) expenses of $20.5 million increased $4.2 million. Selling, marketing, general and administrative expenses (SG&A
- PRTaro to Release Full Year Results on May 20, 2024Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2024, after the close of market on Monday, May 20, 2024. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com. View source version on businesswire.com: https://www.busi
- SECSEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
- SECSEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
- PRLeading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote "FOR" Taro Sun Pharma MergerTaro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that leading independent proxy advisory firms Institutional Shareholder Services ("ISS") and Glass Lewis & Co. ("Glass Lewis") have both recommended that Taro shareholders vote "FOR" the pending Merger transaction with Sun Pharmaceutical Industries Ltd. ("Sun Pharma") at the upcoming May 22, 2024, extraordinary general meeting of shareholders. Taro's shareholders are reminded that the May 19, 2024, deadline for proxy voting is rapidly approaching and are urged to vote "FOR" the transaction, as unanimously recommended by Taro's Special Committee, Board of Directors, Audit Committee and both proxy advi
- PRTaro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced that it has called an extraordinary general meeting of its shareholders (the "Extraordinary General Meeting"), to be held on May 22, 2024, at 10:00 a.m., Israel time, and a class meeting (the "Ordinary Class Meeting" and together with the Extraordinary General Meeting, the "Meetings") of the holders of the Company's ordinary shares (the "Ordinary Shares"), to be held on May 22, 2024, at 11:00 a.m., Israel time, or immediately after the conclusion of the Extraordinary General Meeting, whichever is later, at Meitar Law Offices located at 16 Abba Hillel Road, 10th Floor, Ramat Gan, Israel. Following the O
- SECSEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
- SECSEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
- SECSEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)SC 13E3/A - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
- SECSEC Form SC 13E3 filed by Taro Pharmaceutical Industries Ltd.SC 13E3 - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Subject)
- NEWSKrensavage Asset Management Remains Opposed to Sun Pharma's Predatory Bid for Taro PharmaKrensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical Industries Ltd. Dear Linda, As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE:TARO), Krensavage Asset Management LLC remains opposed to Sun Pharmaceutical Industries Ltd.'s inadequate bid to take Taro private.
- PRKrensavage Asset Management Remains Opposed to Sun's Predatory Bid for TaroNEW YORK, Jan. 30, 2024 /PRNewswire/ -- Krensavage Asset Management today sent the following message to a special committee evaluating Sun Pharmaceutical Industries Ltd.'s bid for Taro Pharmaceutical Industries Ltd. Krensavage Asset Management LLC610 Fifth AvenueSuite 301New York, NY 10020info@krensavage.com Taro Special CommitteeLinda Benshoshanlinda@lindabs.co.il Dear Linda, As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE:TARO), Krensavage Asset Management LLC remains opposed to Sun Pharmaceutical Industries Ltd.'s inadequate bid to take Taro private. Since we expressed our dismay in an open letter July 19, Sun, a 78.5% Taro shareholder, hiked its bid 13
- SECSEC Form 6-K filed by Taro Pharmaceutical Industries Ltd.6-K - TARO PHARMACEUTICAL INDUSTRIES LTD (0000906338) (Filer)